A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma

Yamagami,Wataru; Susumu,Nobuyuki; Ninomiya,Tomomi; Kuwahata,Michiko; Takigawa,Aya; Nomura,Hiroyuki; Kataoka,Fumio; Tominaga,Eiichiro; Banno,Kouji; Tsuda,Hiroshi; Aoki,Daisuke

doi:10.3892/mco.2014.272

A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma

Authors:
- Wataru Yamagami
- Nobuyuki Susumu
- Tomomi Ninomiya
- Michiko Kuwahata
- Aya Takigawa
- Hiroyuki Nomura
- Fumio Kataoka
- Eiichiro Tominaga
- Kouji Banno
- Hiroshi Tsuda
- Daisuke Aoki
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
Published online on: March 31, 2014 https://doi.org/10.3892/mco.2014.272
Pages: 591-595

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is currently insufficient evidence to recommend a specific chemotherapeutic regimen as standard treatment for uterine sarcomas. In this study, we investigated the toxicity and effectiveness of ifosfamide, adriamycin and cisplatin (IAP therapy) in patients with progressive and recurrent uterine sarcoma. A total of 11 patients with progressive or recurrent uterine sarcoma containing leiomyosarcoma (LMS), undifferentiated endometrial sarcoma (UES) or adenosarcoma, who were diagnosed at our institution, were retrospectively investigated. We recorded the adverse events, response rate and progression‑free survival in these cases. The histological types included LMS (54.5%), adenosarcoma (27.3%) and UES (18.2%). Grade ≥3 leukopenia or neutropenia were observed in all the cases, febrile neutropenia developed in 45.5% of the patients and grade 4 thrombocytopenia developed in 3 cases (27.3%). With IAP therapy, the response rate was 36.4% and the disease control rate was 90.9%. Therefore, IAP therapy may be a viable option as chemotherapy for uterine sarcoma.

View Figures

View References

1	Brooks SE, Zhan M, Cote T and Baquet CR: Surveillance, epidemiology, and end results analysis of 2,677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 93:204–208. 2004.
2	Fujita H, Adachi S, Kigawa J, et al: Clinicopathological analysis for uterine sarcoma. Sampu no shimpo. 56:463–465. 2004.(In Japanese).
3	Wada H, Enomoto T, Fujita M, et al: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 57:5379–5385. 1997.PubMed/NCBI
4	Lurain JR: Uterine cancer. Berek & Novak’s Gynecology. Berek JS: 14th edition. Lippincott Williams & Wilkins; Philadelphia: pp. 1343–1402. 2006
5	Goff BA, Rice LW, Fleischhacker D, et al: Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 50:105–109. 1993. View Article : Google Scholar : PubMed/NCBI
6	Sagae S, Yamashita K, Ishioka S, et al: Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology. 67:33–39. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ushijima M, Yamakawa Y, Sakabe E, et al: A case of recurrent high-grade endometrial stromal sarcoma controlled by a combination of ifosfamide, adriamycin, and cisplatin. Jpn J Canc Chemother. 37:2003–2005. 2010.(In Japanese).
8	Yamawaki T, Shimizu Y and Hasumi K: Treatment of stage IV ‘high-grade’ endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin. Gynecol Oncol. 64:265–269. 1997.
9	Omura GA, Major FJ, Blessing JA, et al: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 52:626–632. 1983. View Article : Google Scholar : PubMed/NCBI
10	Sutton GP, Blessing JA, Manetta A, et al: Gynecologic Oncology Group studies with ifosfamide. Semin Oncol. 19:31–34. 1992.PubMed/NCBI
11	Look KY, Sandler A, Blessing JA, Lucci JA III and Rose PG; Gynecologic Oncology Group (GOG). Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 92:644–647. 2004. View Article : Google Scholar : PubMed/NCBI
12	Sutton G, Blessing JA and Ball H: Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 74:346–349. 1999. View Article : Google Scholar : PubMed/NCBI
13	Thigpen JT, Blessing JA, Beecham J, Homesley H and Yordan E: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 9:1962–1966. 1991.PubMed/NCBI
14	Sutton G, Blessing JA and Malfetano JH: Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 62:226–229. 1996. View Article : Google Scholar : PubMed/NCBI
15	Piver MS, DeEulis TG, Lele SB and Barlow JJ: Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. Gynecol Oncol. 14:319–323. 1982. View Article : Google Scholar
16	Hensley ML, Blessing JA, Degeest K, et al: Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 109:323–328. 2008. View Article : Google Scholar
17	Hensley ML, Blessing JA, Mannel R and Rose PG: Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 109:329–334. 2008. View Article : Google Scholar
18	Pearl ML, Inagami M, McCauley DL, et al: Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas. Int J Gynecol Cancer. 12:745–748. 2002. View Article : Google Scholar : PubMed/NCBI
19	Slayton RE, Blessing JA, Angel C and Berman M: Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep. 71:1303–1304. 1987.
20	Sutton G, Blessing J, Hanjani P and Kramer P; Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 96:749–752. 2005. View Article : Google Scholar : PubMed/NCBI
21	Miller DS, Blessing JA, Kilgore LC, Mannel R and Van Le L: Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study. Am J Clin Oncol. 23:355–357. 2000. View Article : Google Scholar : PubMed/NCBI
22	Monk BJ, Blessing JA, Street DG, et al: A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 124:48–52. 2012. View Article : Google Scholar : PubMed/NCBI
23	Yamaguchi M, Yanase T, Yokoo T, et al: Clinical study and treatment of uterine sarcoma at Niigata City General Hospital. Jpn J Canc Chemother. 31:209–213. 2004.(In Japanese).